The Full Federal Court has rejected German drug maker Boehringer Ingelheim’s appeal of ruling that shot down its opposition to Merck Sharp & Dohme’s patent application for an injectable anti-parasite drug for livestock.
The High Court has granted special leave to a cosmetic company to challenge a judgment finding it infringed Botox maker Allergan’s trade marks by marketing its topical creams as Botox alternatives.
Ramsay Health Care Australia has been let off the hook for using emails subpoenaed in a defamation case between two feuding surgeons at one of its hospitals, with a judge accepting that an in-house lawyer was “mortified” by her mistake and was “drowning in work” at the time.
Pharmaceutical giant Pfizer has fired off a lawsuit against four drug companies for allegedly infringing one of its patents for biologic Enbrel by selling a biosimilar of the blockbuster arthritis drug in Australia.
Bayer has dropped its appeal to a ruling that quashed an extension for its patent covering an oral contraceptive, after the Full Court dealt drug makers a blow in two separate cases on how patent term extensions should be calculated.
Discount pharmacy Priceline cannot trade mark the signature bright pink that adorns it shopfront signs and awnings, an IP Australia delegate has found.
Six more fertility clinics in states across the country are set to be pulled into a class action against Monash IVF on behalf of hundreds of men and women demanding damages for the alleged destruction of potentially viable embryos.
Philips Electronics has hit back at a class action over recalled sleep apnea machines that contained a foam component that could allegedly degrade and cause consumers to inhale dangerous chemicals, saying the devices were not defective when they were sold.
Two psychiatrists who administered the controversial deep sleep therapy at the Chelmsford Private Hospital in the 1970s have won a Full Federal Court appeal in their defamation cases against publisher HarperCollins, with one of the cases being sent back for a re-trial.
Settlement talks in three class actions on behalf of women injured by allegedly defective pelvic mesh products have progressed “substantially”, a court has heard.